Equities

Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Actions
  • Price (EUR)0.75
  • Today's Change0.00 / 0.00%
  • Shares traded1.64k
  • 1 Year change+1.15%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 08:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments81278377
Total Receivables, Net1.334.476.36
Total Inventory------
Prepaid expenses121816
Other current assets, total------
Total current assets94300399
Property, plant & equipment, net53126125
Goodwill, net03840
Intangibles, net05154
Long term investments03088
Note receivable - long term------
Other long term assets171614
Total assets165563722
LIABILITIES
Accounts payable15229.76
Accrued expenses213431
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total125588
Total current liabilities48112128
Total long term debt000
Total debt000
Deferred income tax06.276.65
Minority interest----0
Other liabilities, total35150212
Total liabilities82268347
SHAREHOLDERS EQUITY
Common stock1.781.671.46
Additional paid-in capital1,4921,4501,334
Retained earnings (accumulated deficit)(1406)(1149)(956)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(4.6)(8.4)(3.99)
Total equity83295375
Total liabilities & shareholders' equity165563722
Total common shares outstanding178167146
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.